Core Points - Xenon Pharmaceuticals Inc. has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution effective June 27, 2025 [1] - The Russell 3000® Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization, while the Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. indexes, making them widely used by investment managers and institutional investors [3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics [4] - The company is advancing an ion channel product portfolio to address high unmet medical needs, including epilepsy and depression [4] - Azetukalner, a novel and highly potent selective Kv7 potassium channel opener, is the most advanced clinically validated potassium channel modulator in late-stage clinical development for multiple indications [4]

Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indicationsVANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief ...

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025. Fireside Chat Presentation Details: Date:Tuesday, June 10, 2025 Time:3:20-3:55 PM Eas ...

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need [3] - The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression [3] - Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, is highlighted as the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications [3] Event Participation - Xenon Pharmaceuticals will present at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY, on May 20-21, 2025 [1] - The presentation will take place on May 21, 2025, from 10:30-10:55 AM Eastern Time, featuring Ian Mortimer, President and Chief Executive Officer [2] - A live audio webcast of the presentation will be available on the "Investors" section of Xenon's website and will be posted for replay following the event [2]

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - ...